stockrowRedhill Biopharma Ltd. (RDHL) vs China SXT Pharmaceuticals, Inc. (SXTC)
- Redhill Biopharma Ltd. RDHL 0.43 0.00%
- China SXT Pharmaceuticals, Inc. SXTC 2.92 −0.34%
Redhill Biopharma Ltd. and China SXT Pharmaceuticals, Inc. are both Drug Manufacturers Specialty & Generic companies. Redhill Biopharma Ltd. is the larger, with a market value of $3.8M against $2.0M — 1.9× the size. China SXT Pharmaceuticals, Inc. grew revenue faster over the last twelve months: −54.0% against −61.9%. Redhill Biopharma Ltd. has the higher net margin (25.2% vs −255.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, China SXT Pharmaceuticals, Inc. leads on 7 and Redhill Biopharma Ltd. on 4.
Valuation
| Metric | RDHL | SXTC | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| P/E | n/m | n/m | 20.55 |
| P/S | 0.00 | n/m | 2.08 |
| P/B | n/m | n/m | 1.79 |
| Price to free cash flow | n/m | n/m | 16.29 |
| EV/EBITDA | n/m | 2.66 | 12.22 |
| EV/Sales | 6.43 | (5.94) | 2.87 |
| Earnings yield | (142,015.51%) | (3,722.74%) | (15.94%) |
| Free cash flow yield | (231,394.02%) | 0.00% | 0.00% |
Profitability
| Metric | RDHL | SXTC | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 35.16% | 36.69% | 53.51% |
| Operating margin | 0.00% | 0.00% | 0.00% |
| Net margin | 25.20% | (255.16%) | (2.45%) |
| Free cash flow margin | 0.00% | 0.00% | 0.00% |
| Return on equity | 0.00% | 0.00% | (0.80%) |
| Return on assets | 0.00% | 0.00% | (1.67%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack